UNITED GUARDIAN INC Annual Report - How They Did This Year

I’m writing this guide to help you understand how United-Guardian, Inc. (UG) performed this year. My goal is to explain their business in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

United-Guardian is a specialty chemical company based in Hauppauge, New York. They act as a "behind-the-scenes" supplier, making ingredients for personal care products, medical lubricants, and pharmaceuticals. They focus on "green" and sustainable ingredients, a growing trend in the cosmetic industry. The company keeps things simple, using one manufacturing facility that meets strict FDA and global quality standards.

2. Financial performance: A major shift

The company is changing. Their traditional cosmetic business is shrinking, while their pharmaceutical business is now their main engine.

• Pharmaceuticals: This is now their biggest segment. It grew to 51% of total sales in 2025 ($7.2 million), up from 39% in 2024. Their key drug, Renacidin, is the only FDA-approved product for dissolving bladder stones. This gives them a stable, protected position in that market.
• Cosmetics: Sales accounted for 29% of total sales in 2025 ($4.1 million), down from 45% in 2024. This decline reflects shifting consumer tastes and changes in their customer base.
• Medical Lubricants: This segment remains steady, representing 20% of total sales ($2.8 million), driven by consistent demand for their Lubrajel line of gels.

3. Major wins and changes

• New Growth Areas: They are pivoting toward "sexual wellness" ingredients. They launched Natrajel®—a vegan, biodegradable, silicone-free product—and signed a deal to sell it in France. They expect this to boost their European market share by 5-8% by late 2026.
• Distribution Shake-up: They are renegotiating a contract with their largest distributor, Ashland Specialty Ingredients (ASI), which brings in about 25% of their revenue. If this changes, the company plans to sell directly to customers or use smaller regional distributors.
• Pharmaceutical Strategy: They are working to get Renacidin covered by more insurance plans. By securing preferred status on three major pharmacy benefit manager lists, they expect a 10% volume increase in 2026.

4. Financial health and strategy

United-Guardian is very conservative. They have no debt and hold about $12 million in cash. They don't use patents, preferring to keep their "secret recipes" private. They manufacture almost everything in New York to ensure high quality. They recently earned a new "Good Manufacturing Practice" certification, which helps them expand their pharmaceutical services.

5. Key risks

• Customer Concentration: They rely heavily on a few distributors. If the relationship with ASI fails, they could lose up to $3.5 million in revenue.
• Pricing Pressure: Low-cost competitors in Asia and Eastern Europe are a threat. UG fights this by focusing on high-quality, "green" ingredients to keep their profit margins high.
• Product Reliance: Nearly 70% of their revenue comes from just two products: Renacidin and Lubrajel. If these products face new competition, the company lacks a large catalog to fall back on, which could threaten their dividend payouts.

6. Future outlook

The company is working to diversify. Their 2026 success depends on whether Natrajel gains traction and if their insurance-focused marketing for Renacidin pays off. Management plans to keep paying their dividend while reinvesting 15% of their cash flow into research for new, sustainable ingredients.

Investor Takeaway: United-Guardian is a debt-free, cash-rich company currently in a transition phase. If you are looking for a stable, dividend-paying company, their pharmaceutical segment provides a strong foundation. However, keep a close eye on the outcome of their distributor negotiations and the adoption of their new Natrajel product, as these will be the primary drivers of their growth in the coming year.